Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) AI Stock Analysis

• Market Cap: €51.57B
• Dividend Yield: 0.68%
• Average Volume (3M): 3.33M
• Price to Earnings (P/E): 120.2
• Beta (1Y): 1.88
• Revenue Growth: -7.88%
• EPS Growth: -73.16%
• Country: HK
• Employees: 10,185
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.27
• Shares Outstanding: 123,124,800
• 10 Day Avg. Volume: 4,434,758
• 30 Day Avg. Volume: 3,332,687
• PEG Ratio: -0.77
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 3.79
• P/FCF Ratio: 33.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €55.68
• Price Target Upside: 18.33% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 61 Neutral
• Price Target: HK$50.00 ▲(6.25% Upside)

The overall stock score of 61 reflects strong financial performance with robust operational margins and a solid balance sheet. However, the high P/E ratio suggests overvaluation, and technical indicators point to bearish momentum. The lack of earnings call data and corporate events further limits the assessment.

Hangzhou Tigermed Consulting Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

How the Company Makes Money

Hangzhou Tigermed Consulting Co., Ltd. generates revenue primarily through its clinical trial services, which include project management, site management, patient recruitment, and regulatory consulting. The company's revenue model is based on service fees charged to clients for each project or service rendered. Key revenue streams include contracts with pharmaceutical and biotechnology firms for conducting clinical trials, as well as consulting services related to regulatory compliance and market access strategies. Additionally, Tigermed may benefit from strategic partnerships with global pharmaceutical companies, which can lead to long-term contracts and increased project volume, further enhancing its earnings potential.

Hangzhou Tigermed Consulting Co., Ltd. Class H Financial Statement Overview

Summary

Hangzhou Tigermed Consulting Co., Ltd. Class H demonstrates strong operational margins and a solid balance sheet, highlighting financial prudence. However, declining revenues and net income in the TTM, coupled with reduced operating cash flow, pose challenges for future growth and liquidity. Strengthening revenue generation and cash flow will be critical for sustaining financial health.

Income Statement

The company's gross profit margin and EBIT margin are strong, indicating efficient cost management and operational performance. However, revenue and net income have declined in the TTM, showing a negative growth trend. Despite this, the company maintains a healthy EBITDA margin, suggesting resilience in operational profitability.

Balance Sheet

The debt-to-equity ratio is low, indicating prudent financial leverage. The equity ratio is high, reflecting financial stability and strong asset backing. Return on equity has declined, suggesting a need for improved profitability to enhance shareholder returns.

Cash Flow

Operating cash flow has decreased significantly in the TTM, raising concerns about cash generation from core operations. The free cash flow to net income ratio is positive, but lower operating cash flow may impact future liquidity. The company has maintained positive free cash flow, albeit at a reduced level.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.50B	6.60B	7.38B	7.09B	5.21B	3.19B
Gross Profit	1.89B	2.24B	2.85B	2.81B	2.27B	1.51B
EBITDA	833.61M	1.13B	2.91B	2.42B	2.11B	1.27B
Net Income	703.92M	405.14M	2.02B	2.01B	2.87B	1.75B
Balance Sheet
Total Assets	28.50B	28.67B	29.68B	27.45B	23.74B	19.51B
Cash, Cash Equivalents and Short-Term Investments	1.82B	2.13B	7.46B	7.88B	8.57B	10.15B
Total Debt	2.38B	2.63B	2.83B	2.80B	1.19B	384.94M
Total Liabilities	4.54B	4.61B	5.23B	4.77B	3.14B	1.65B
Stockholders Equity	20.52B	20.67B	21.03B	19.58B	18.12B	16.12B
Cash Flow
Free Cash Flow	747.53M	740.45M	836.68M	908.90M	1.06B	842.18M
Operating Cash Flow	408.62M	1.10B	1.15B	1.36B	1.42B	998.68M
Investing Cash Flow	1.03B	-4.74B	-1.53B	―	―	―
Financing Cash Flow	-723.08M	-1.70B	-7.81M	809.25M	―	9.34B

Hangzhou Tigermed Consulting Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 47.06
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3347, the sentiment is Positive. The current price of 47.06 is below the 20-day moving average (MA) of 48.28, below the 50-day MA of 51.27, and above the 200-day MA of 37.11, indicating a neutral trend. The MACD of -1.27 indicates Positive momentum. The RSI at 47.72 is Neutral, neither overbought nor oversold. The STOCH value of 47.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3347.

Hangzhou Tigermed Consulting Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6821	69 Neutral	40.83B	29.47	―	1.26%	6.68%	-0.96%
2276	67 Neutral	20.62B	36.26	27.01%	0.79%	13.58%	24.59%
3759	67 Neutral	62.67B	31.52	―	0.82%	13.51%	-28.45%
2367	64 Neutral	57.21B	25.83	29.01%	1.07%	36.70%	22.26%
3347	61 Neutral	€51.57B	120.16	1.40%	0.68%	-7.88%	-73.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Hangzhou Tigermed Consulting Co., Ltd. Class H Corporate Events

Hangzhou Tigermed Announces 2025 Extraordinary General Meeting to Approve Key Resolutions

Hangzhou Tigermed Consulting Co., Ltd. has announced the convening of its 2025 first extraordinary general meeting to discuss and approve several key resolutions. These include amendments to the company’s Articles of Association, Rules of Procedure for General Meetings and Board of Directors’ Meetings, and a proposal to reduce registered capital. The meeting will also address amendments to various management rules and grant authority to negotiate audit fees, reflecting the company’s ongoing efforts to refine its governance and operational frameworks.

The most recent analyst rating on (HK:3347) stock is a Hold with a HK$54.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

Hangzhou Tigermed Proposes Governance Amendments to Enhance Operations

Hangzhou Tigermed Consulting Co., Ltd. has announced proposed amendments to its Articles of Association and corporate governance rules to align with the latest legal and regulatory standards. These changes aim to enhance the company’s operational efficiency and governance structure, reflecting its commitment to standardized operations and improved shareholder relations. The proposed amendments require shareholder approval and are designed to refine the company’s governance framework, thereby potentially strengthening its market position and stakeholder trust.

The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

Hangzhou Tigermed Appoints Wu Hao as Employee Director

Hangzhou Tigermed Consulting Co., Ltd. announced the election of Mr. Wu Hao as the employee director for the fifth session of its board, following proposed amendments to its Articles of Association. Mr. Wu, who has extensive experience in the pharmaceutical industry, will continue to serve as an executive director and a member of the strategy development committee, enhancing the company’s governance structure and strategic direction.

The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

Hangzhou Tigermed Enhances Governance with New Audit Committee

Hangzhou Tigermed Consulting Co., Ltd. has established an Audit Committee under its board of directors to enhance decision-making and corporate governance. The committee, composed of independent directors with accounting expertise, is tasked with overseeing external audit processes, ensuring auditor independence, and managing auditor appointments and dismissals. This move is expected to strengthen the company’s governance structure and improve oversight of senior management, potentially impacting its industry positioning positively.

The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

Hangzhou Tigermed Enhances Governance with New Nomination Committee

Hangzhou Tigermed Consulting Co., Ltd. has established a Nomination Committee to enhance its corporate governance structure by improving the appointment procedures for directors and senior management. This committee is tasked with nominating candidates for these positions, ensuring a balanced and diverse board composition, and making recommendations on selection criteria and procedures. The initiative is expected to strengthen the company’s governance framework, potentially impacting its operational efficiency and stakeholder confidence.

The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

Hangzhou Tigermed Enhances Governance with New Committee

Hangzhou Tigermed Consulting Co., Ltd. has established a Remuneration and Evaluation Committee to improve its corporate governance structure. This committee is responsible for formulating evaluation standards and remuneration policies for directors and senior management, ensuring accountability to the board of directors. The committee’s establishment is expected to enhance transparency and formalize procedures for remuneration policies, potentially impacting the company’s operational efficiency and stakeholder trust.

The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

Hangzhou Tigermed Forms Strategy Development Committee to Enhance Strategic Planning

Hangzhou Tigermed Consulting Co., Ltd. has established a Strategy Development Committee to strengthen its strategic planning and investment decision-making processes. This move aims to improve the company’s long-term development strategies and ensure effective management of significant investments, thereby potentially enhancing its market position and operational efficiency.

The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

Hangzhou Tigermed Reports Decline Amid Biopharmaceutical Industry Shifts

Hangzhou Tigermed Consulting Co., Ltd. reported a decline in its financial performance for the first half of 2025, with revenue, gross profit, and net profit all decreasing compared to the same period in 2024. The company attributes these challenges to the volatile demand for R&D in the domestic biopharmaceutical industry, influenced by global macroeconomic cycles and shifts in client risk appetites. Despite these challenges, the company remains optimistic about future opportunities, as China’s biopharmaceutical industry continues to advance with a focus on high-quality, innovative R&D projects.

The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

Hangzhou Tigermed Consulting Schedules Board Meeting to Review Interim Results

Hangzhou Tigermed Consulting Co., Ltd. has announced a board meeting scheduled for August 28, 2025, to review and approve the company’s unaudited interim results for the first half of 2025. The meeting will also consider the declaration and payment of an interim dividend, which could impact the company’s financial positioning and shareholder returns.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$38.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.